Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q96NN9
UPID:
AIFM3_HUMAN
Alternative names:
Apoptosis-inducing factor-like protein
Alternative UPACC:
Q96NN9; B7WP37; D3DX37; D3DX38; Q6ZT44; Q8N1V3; Q8N5E0
Background:
Apoptosis-inducing factor 3, also known as Apoptosis-inducing factor-like protein, plays a pivotal role in cellular processes by inducing apoptosis through a caspase-dependent pathway. This protein is instrumental in reducing mitochondrial membrane potential, a critical step in the apoptosis mechanism.
Therapeutic significance:
Understanding the role of Apoptosis-inducing factor 3 could open doors to potential therapeutic strategies. Its ability to regulate cell death positions it as a key target for interventions in diseases where apoptosis is dysregulated.